– 95% of patients achieved normal pH exposure levels following concomitant HHR and TIF 2.0 procedures – – GERD-related quality of life and reflux symptom scores also improved significantly – REDMOND, Wash. – EndoGastric Solutions today announced the publication of new clinical data demonstrating high rates of pH normalization and improved clinical outcomes in patients […]

Amit Sohagia, MD received ACG’s Outstanding Poster Presenter Award for TIF 2.0 procedure poster REDMOND, Wash. – EndoGastric®Solutions today announced the presentation of three posters at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting and Postgraduate Course, highlighting the safety and efficacy of Transoral Incisionless Fundoplication (TIF) 2.0 procedure in the treatment of gastroesophageal […]

Existing and New Investors Participated in Support of Rapid Commercialization Redmond, Washington. – EndoGastric Solutions® (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), announced today that it has secured $30.5 million in new financing led by existing EGS investors Advanced Technology Ventures (ATV), Canaan Partners, Canepa Healthcare, Chicago Growth Partners, CRG, Radius […]

TIF 2.0 Procedure improves symptoms and esophagitis while reducing acid exposure and decreasing risk associated with long-term proton pump inhibitor use for POEM patients REDMOND, Wash – EndoGastric® Solutions today announced the publication of new clinical data demonstrating the safety and efficacy of the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure in patients with achalasia who have […]